What's in BioMarin Pharmaceutical Inc.'s pipeline?

BioMarin Pharmaceutical Inc. has 6 drugs in our index: 6 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with BioMarin Pharmaceutical Inc.'s portfolio?

Top competitors by shared drug class: Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/biomarin.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

BioMarin Pharmaceutical Inc. — Portfolio Competitive Intelligence Brief

BioMarin Pharmaceutical Inc. (BMRN) pipeline: 6 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

BMRN (NASDAQ) 6 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Roctavian	VALOCTOCOGENE ROXAPARVOVEC	marketed			Rare Disease	2022-01-01
Rhttp1	CERLIPONASE ALFA	marketed	Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase		Neuroscience	2017-01-01
Rhgalns	ELOSULFASE ALFA	marketed	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]	N-acetylgalactosamine-6-sulfatase	Metabolic	2014-01-01
Kuvan	SAPROPTERIN	marketed	Phenylalanine Hydroxylase Activator	Nitric oxide synthase, brain	Oncology	2007-01-01
Aryplase	GALSULFASE	marketed	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]		Metabolic	2005-01-01
Aldurazyme	LARONIDASE	marketed	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]		Metabolic	2003-01-01

Therapeutic area mix

Metabolic · 3
Neuroscience · 1
Oncology · 1
Rare Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Takeda · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BioMarin Pharmaceutical Inc.:

Cite this brief

Drug Landscape (2026). BioMarin Pharmaceutical Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biomarin. Accessed 2026-05-13.